Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.

Maribavir as good as valganciclovir for cytomegalovirus infection in transplant recipients

07 Nov 2019

Maribavir 400 mg twice daily appears to have comparable efficacy to valganciclovir at clearing cytomegalovirus (CMV) viraemia in transplant recipients, a study has found.

The phase II, open-label trial randomized 161 recipients of haematopoietic-cell or solid-organ transplants with CMV reactivation (1,000 to 100,000 DNA copies per millilitre) to receive maribavir at a dose of 400, 800 or 1,200 mg twice daily or the standard dose of valganciclovir for no more than 12 weeks.

Of the patients, 159 received treatment and 156 had postbaseline data available (117 in the maribavir groups and 39 in the valganciclovir group). Response to treatment within 3 weeks occurred in 62 percent of patients in the combined maribavir groups and 56 percent in the valganciclovir group. Within 6 weeks of treatment, 79 percent and 67 percent of patients had a response (risk ratio, 1.20, 95 percent confidence interval, 0.95–1.51). Treatment response did not differ among the maribavir dose groups.

CMV infection recurred within 6 weeks in two patients who received maribavir at a dose of 800 mg twice daily. Both patients developed T409M resistance mutations in CMV UL97 protein kinase.

Serious adverse events that occurred or worsened during treatment were higher in the maribavir group than in the valganciclovir group (44 percent vs 32 percent). Adverse events leading to trial discontinuation also occurred with greater frequency in the former (23 percent vs 12 percent). Gastrointestinal adverse events were common with maribavir, whereas neutropaenia was reported more frequently with valganciclovir.

Maribavir, especially given its unique mechanism of action and evidence suggesting a lack of myelosuppression, should be explored further in patients who have undergone transplantation, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.